Enlivex Therapeutics
ENLV
ENLV
19 hedge funds and large institutions have $795K invested in Enlivex Therapeutics in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less ownership
Funds ownership: →
36% less capital invested
Capital invested by funds: $1.24M → $795K (-$443K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Holders
19
Holding in Top 10
–
Calls
$172K
Puts
$27K
Top Buyers
| 1 | +$9.7K | |
| 2 | +$6.07K | |
| 3 | +$5.26K | |
| 4 |
AAP
Arax Advisory Partners
Denver,
Colorado
|
+$762 |
Top Sellers
| 1 | -$35.8K | |
| 2 | -$32.6K | |
| 3 | -$28.5K | |
| 4 |
Goldman Sachs
New York
|
-$19.9K |
| 5 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
-$7.3K |